An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

Genentech

Status: Completed

Conditions: Psoriasis; Pregnancy

Study type: Observational

Funder types: Industry

Identifiers

NCT00097240

ACD3100g

Details and patient eligibility

About

The Raptiva Pregnancy Registry was a prospective observational study established to obtain data on pregnancy outcomes of women who were exposed to Raptiva.

Enrollment: 18 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Any patient who has used Raptiva within 6 weeks prior to conception or during her pregnancy may be included in the Registry. Enrollment is based on Raptiva exposure, whether inadvertent or deliberate, in relation to pregnancy. Enrollment should occur as early as possible during the pregnancy and must occur prior to knowledge of pregnancy outcome.